MariMed Business Model Canvas

Reliable suppliers deliver genetics, nutrients, substrates, hardware, and compliant packaging that ensure consistent terpenes, potency, and regulatory labeling. Volume agreements stabilize cost and supply continuity, reducing procurement risk and smoothing production planning. Co-development with suppliers enhances sustainability and shelf appeal through optimized materials and formulations, while supplier quality directly affects yields, unit economics, and product integrity.

Strategic regulators, labs, suppliers, retail wholesalers and fintech/tech partners enable MariMed to scale compliantly across 38 medical and 23 adult‑use states (2024). Testing (24–72h), supply agreements and seed‑to‑sale systems reduce licensing, quality and inventory risk while supporting national wholesale distribution. These partnerships helped leverage a ~30B USD U.S. legal market (2024) and ~10% retail sales growth.

Owned dispensaries deliver curated consumer experiences and capture point-of-sale and loyalty data to inform assortment and pricing strategies.

Wholesale teams manage key accounts, dynamic pricing and product allocations to maximize distribution and margin across channels.

Merchandising, promotions and demand forecasting align production with market trends to drive velocity and optimize inventory turnover.

Core activities: controlled cultivation targeting 500–700 g/m2 and 20–30% THC with SOPs and METRC traceability; extraction and formulation to supply multi-category SKUs with GMP-like batch records; retail and wholesale distribution capture POS data to optimize assortment and pricing; compliance, audits and recall readiness manage regulatory risk amid >30 billion USD US legal cannabis sales (2024).

Experienced cultivators, processors, pharmacists, and retail staff deliver consistent execution at MariMed, leveraging 15 years of operational experience since 2009. Documented SOPs enable repeatability and training, supporting scale across product lines. Cross-functional teams manage compliance, safety, and QA with centralized oversight. Institutional knowledge shortens troubleshooting cycles and reduces onboarding time.

Licenses, cultivation/dispensary assets and proprietary genetics form MariMed’s high-value backbone, enabling scalable margins in a US legal cannabis market ~30B (2023–24). Experienced ops teams, SOPs and seed-to-sale systems ensure compliance, consistency and analytics-driven pricing. Recognized brands and hundreds of retail partners (MRMD public) secure distribution and premium placement.

Diverse product portfolio—flower, vapes, concentrates, edibles, and wellness formats—meets varied consumer needs and supports cross-category purchasing; U.S. legal cannabis sales exceeded 25 billion in 2024, underlining scale. Multiple price tiers capture budget-conscious and premium buyers, widening market reach. Continuous product innovation keeps assortments fresh and drives retailer velocity, offering a one-stop lineup that boosts store turnover.

End-to-end seed-to-sale ensures consistent quality and traceability, supporting MariMed in a ~30B US legal cannabis market (2024). Rigorous third-party QA and compliance across 38 medical states (2024) drive trust and repeat purchases. Data-driven forecasting cuts waste ~30% and raises turns 15–25%, enabling multi-format assortments and faster market launches.

Consultative service matches MariMed products to patient needs and tolerances, leveraging clinician-trained staff to reduce adverse reactions and improve adherence. Clear dosing guidance—aligned with best-practice protocols—enhances safety and outcomes. Responsive channels resolve issues, collect feedback and track metrics (response targets often within 24 hours). Trust grows through consistent, empathetic interactions; U.S. legal cannabis sales topped $30 billion in 2023, underscoring scale and demand for quality support.

Tiered rewards, segmentation and personalized offers drive retention; U.S. legal cannabis sales grew from about 25B in 2023 to ~30.9B in 2024, highlighting scale for loyalty programs. Budtender training, sampling and product guides raise conversion and AOV; clinician-trained consults and 24h response targets improve adherence and safety. B2B reps, 98% fill-rate SLAs and co-marketing lift retail sell-through.

Online menus with real-time inventory enable pre-orders and reduce cancellations, supporting MariMed retail as US e-commerce reached 18.9% of retail sales in 2024. Pickup and curbside operate within state cannabis regulations and capture a growing share of orders. Optimized digital UX lifts basket size (AOV up to 25% higher) while integrated POS and fulfillment systems streamline order flow and cut pick/pack time.

Company stores, wholesale, online/pickup and licensed delivery form MariMed’s omnichannel reach, capturing share in a US legal cannabis retail market ~30B (2024) with e‑commerce at 18.9% (2024). Company stores drive AOV and data-led assortment; wholesale secures placement and retailer loyalty; online/curbside and delivery (23 states + DC, 2024) boost convenience and retention.

Independent and chain retailers rely on dependable supply and healthy margins; MariMed’s wholesale assortment fills category gaps across flower, vape, and edibles, supporting retailers as the U.S. legal cannabis market was projected by BDSA to top $36 billion in 2024. Retail programs fund promotions and staff training, while sharing POS and SKU-level data with partners improves sell-through and inventory turns.

Recreational consumers seek variety, clear dosing, and value; US adult-use sales ≈ $30B in 2024. Medical patients demand consistent dosing, safety and clinician alignment; ~20% of adults report chronic pain (CDC). Retailers and white-label partners prioritize margin, supply reliability and compliant scale; MariMed supports with catalog breadth and B2B programs.

Licensing fees in major US markets often exceed $100,000 annually, audits and lab tests commonly run $50–$250 per batch, and compliance teams spend 3–6% of revenue on documentation and training; insurance premiums in 2024 averaged about 1–3% of revenue for cannabis operators, with robust compliance programs materially reducing fines and operational disruptions.

MariMed cost base: cultivation COGS driven by energy (30–60% of controllable op-ex in 2024), inputs, labor and maintenance; yield/potency gains lift margins. Retail costs: labor 10–15% of sales, rent $20–40/sqft in key markets; distribution adds 15–25% logistics. SG&A ~35% of revenue (2024); 280E and insurance (1–3% rev) compress net income.

Contract manufacturing and white-label services generate fee income and volume leverage, with MariMed reporting manufacturing-driven revenue growth in 2024 that bolstered product sales and margins. Custom formulations and packaging command premium pricing, increasing per-SKU revenue and supporting gross-margin expansion. Consistently meeting production timelines improved partner retention and repeat orders. Higher plant utilization reduced unit fixed costs, improving fixed-cost absorption.

Retail (avg basket $80; 2–3 visits/month in 2024) and wholesale (US legal sales $26.9B in 2023) drive core revenue; loyalty and store expansion lift AOV and frequency. Contract manufacturing and white-labels, plus reported 2024 manufacturing-driven revenue growth, increase margins. Licensing/royalties and management fees create recurring, capital-light income aligned to partner sell-through.